Q1 Earnings Forecast for Belite Bio Issued By HC Wainwright

Belite Bio, Inc (NASDAQ:BLTE - Free Report) - HC Wainwright dropped their Q1 2025 earnings per share estimates for Belite Bio in a research report issued to clients and investors on Tuesday, March 18th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of ($0.37) per share for the quarter, down from their previous estimate of ($0.32). HC Wainwright has a "Buy" rating and a $100.00 price objective on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio's Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.36) EPS, Q4 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.46) EPS.

A number of other equities research analysts have also recently commented on BLTE. Benchmark lifted their price target on shares of Belite Bio from $57.00 to $79.00 and gave the stock a "buy" rating in a report on Tuesday, January 21st. Cantor Fitzgerald restated an "overweight" rating on shares of Belite Bio in a research note on Tuesday, March 18th.

Belite Bio Stock Performance

BLTE traded down $0.34 during midday trading on Thursday, reaching $66.94. The company had a trading volume of 27,815 shares, compared to its average volume of 49,762. Belite Bio has a 12-month low of $31.01 and a 12-month high of $86.53. The business has a 50-day moving average price of $59.71 and a two-hundred day moving average price of $61.14. The stock has a market cap of $2.13 billion, a PE ratio of -60.31 and a beta of -1.54.

Remove Ads

Belite Bio (NASDAQ:BLTE - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02).

Institutional Trading of Belite Bio

A number of institutional investors have recently modified their holdings of BLTE. Advisors Preferred LLC bought a new stake in Belite Bio during the 4th quarter valued at $52,000. GAMMA Investing LLC raised its stake in shares of Belite Bio by 48.1% during the 4th quarter. GAMMA Investing LLC now owns 1,290 shares of the company's stock valued at $81,000 after purchasing an additional 419 shares during the period. BNP Paribas Financial Markets purchased a new stake in Belite Bio during the 4th quarter worth about $155,000. XTX Topco Ltd bought a new position in Belite Bio in the 3rd quarter worth about $253,000. Finally, JPMorgan Chase & Co. grew its holdings in Belite Bio by 7,122.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 6,356 shares of the company's stock valued at $298,000 after buying an additional 6,268 shares in the last quarter. 0.53% of the stock is currently owned by hedge funds and other institutional investors.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.